Axinn associate Thomas Hedemann, who represents Natco, was mentioned in Aaron Vehling's article, "BIO, PhRMA Ask Fed. Circ. to Revisit Double-Patent Ruling," which appeared on Law360.

Click here to access the article. A subscription is required.